Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco Galaxy Bitcoin ETF (BTCO) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

Invesco Galaxy Bitcoin ETFTrade
Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

Invesco Galaxy Bitcoin ETF vs Charles River Laboratories Intl. Inc — how do they compare? Invesco Galaxy Bitcoin ETF trades at $62.92, while Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.

BTCOCRL
Sector
Crypto-linkedHealth
52-Week High
$125.14$282.00
52-Week Low
$58.40$145.57
Market Cap
$13.46B
Enterprise Value
$16.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco Galaxy Bitcoin ETF

BTCO trades at $63.03, down 0.93% for the session. Technical indicators show a bullish trend with moving averages supporting upward momentum, while oscillators remain neutral. The stock faces resistance at $65 with support at $64. Recent financial data shows key valuation and profitability metrics are currently unavailable for analysis.

The stock's technical setup suggests potential for near-term upside if resistance levels are breached. However, the absence of fundamental financial metrics creates significant uncertainty about the company's underlying business performance and valuation. Investors face elevated risk due to limited visibility into financial health and operational metrics.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Returns comparison

Trailing returns across standard periods

About Invesco Galaxy Bitcoin ETF

BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.

Read more on BTCO

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL